Author:
Regidor Bernard,Goldwater Marissa-Skye,Wang Jessica,Bujarski Sean,Swift Regina,Eades Benjamin,Emamy-Sadr Marsiye,Eshagian Shahrooz,Schwartz Gary,Spektor Tanya M.,Berenson James R.
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference17 articles.
1. Harousseau J-L, Dreyling M (2010) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v155–v157. https://doi.org/10.1093/annonc/mdq178
2. Dimopoulos MA, Richardson PG, Moreau P, Anderson KC (2014) Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 12:42–54. https://doi.org/10.1038/nrclinonc.2014.200
3. Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927–937. https://doi.org/10.1038/nrc952
4. AbbVie, Inc., Genentech, Inc. Venclexta (venetoclax) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208573s013lbl.pdf. Accessed 28 Oct 2020
5. Merz M, Jauch A, Hielscher T et al (2017) Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv 2:1–9. https://doi.org/10.1182/bloodadvances.2017013334
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献